What Stimdia Medical does

Stimdia Medical, Inc. is a private U.S. medical device company developing a phrenic nerve neuromodulation system (branded SPAIRO and historically referenced as pdSTIM) intended to accelerate weaning of adult ICU patients from mechanical ventilation. The device uses proprietary sensing and electrical stimulation delivered to the phrenic nerves in concert with mechanical ventilation, targeting ventilator-induced diaphragm dysfunction (VIDD) and the approximately one million U.S. adults per year who require invasive mechanical ventilation, of whom only 65% achieve successful liberation within 90 days. The system is a Class III medical device currently advancing through a pivotal FDA study; no commercial launch or pricing has been disclosed.

The company is headquartered in Minnesota (Eagan/Minneapolis) and operates with 11-50 employees. Its senior leadership is drawn almost entirely from Boston Scientific Neuromodulation and Nalu Medical, with the VP of R&D co-holding 60+ U.S. patents, and the CFO having guided prior medical device companies through acquisition exits (Atritech to Boston Scientific, Zyga to RTI Surgical). The board includes representation from lead investors Solas BioVentures and Draper Triangle Ventures, a director from Fresenius Medical Care, and a multi-institution Medical Advisory Board spanning Mayo Clinic, Thomas Jefferson, Duke, WashU Olin, and WakeMed.

Stimdia has raised approximately $21M across a 2015 seed, 2018 and 2019 follow-ons, and a 2022 Series B initial close of $16M (tranche of a planned $30M) co-led by Solas BioVentures and Draper Triangle Ventures. Revenue will be generated post-FDA approval through direct hospital sales of hardware into ICU and critical care departments, with an early academic collaboration with the University of Minnesota in the technology's development history. The company is currently pre-revenue.

Name

Stimdia Medical

Legal name

Stimdia Medical, Inc.

Website

https://stimdia.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Stimdia Medical is a Minnesota-based medical device company developing the SPAIRO System, a phrenic nerve neuromodulation device intended to help adult ICU patients wean from mechanical ventilation. The company is pre-revenue and currently advancing the Class III device through a pivotal FDA study.

Ownership category

akta.pro rank

Product category

Critical Care Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home) (HLAHAGAC)

Keywords

• Phrenic nerve stimulation
• Mechanical ventilation weaning
• Neuromodulation medical devices
• Diaphragm dysfunction therapy
• ICU respiratory support

Headquarters

HQ city

Eagan

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Revenue will be generated through the sale of the SPAIRO System hardware to hospitals and healthcare systems. As a Class III medical device requiring FDA approval, the company will sell the neuromodulation system to healthcare institutions for use in ICU settings to treat mechanically ventilated patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Stimdia Medical is developing the SPAIRO System (also referred to as the pdSTIM System), a phrenic nerve neuromodulation device for adult ICU patients on mechanical ventilation. The system uses proprietary sensing and electrical stimulation to engage the phrenic nerves and diaphragm in concert with mechanical ventilation, intended to restore respiratory drive, reduce ventilator-induced diaphragm dysfunction, and accelerate weaning back to independent breathing.

Product overview

Stimdia Medical is developing neuromodulation technology for patients on mechanical ventilation. The company offers the SPAIRO System, an innovative phrenic nerve neuromodulation device designed to support respiratory drive and help patients return to independent breathing. The system uses proprietary sensing and electrical stimulation technology delivered in concert with mechanical ventilation. The company's technology pipeline also includes the pdSTIM System, which is referenced in funding announcements as a neurostimulation technology for diaphragm strengthening.

Differentiator

Problem solved

Functional benefit

Brands

• SPAIRO System: An innovative phrenic nerve neuromodulation system designed to support respiratory drive and neuromuscular activity in mechanically ventilated adult patients. The system uses proprietary sensing and neuromodulation technology to deliver electrical stimulation to the phrenic nerves in concert with mechanical ventilation, intended to get patients back to independent breathing.
• pdSTIM System

Products and services

• SPAIRO System (also referenced as pdSTIM System) Class III phrenic nerve neuromodulation device that uses proprietary sensing and electrical stimulation to support respiratory drive and diaphragm activity in adult ICU patients on mechanical ventilation, intended to accelerate weaning back to independent breathing.

Quantifiable outcome

• Only 65% of patients requiring mechanical ventilation for 2+ days achieve successful liberation within 90 days
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• University of MinnesotacoreStrategic or Co-development Partner · 14 July 2022Stimdia Medical collaborated with the University of Minnesota during its early development phase. This academic partnership contributed to the development of the company's neurostimulation technology for diaphragm strengthening in mechanically ventilated patients.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Liberate Medical: Liberate Medical is developing a non-invasive neuromuscular electrical stimulation platform to reduce ventilation duration in ICU patients - direct overlap with SPAIRO on patient population, clinical setting, and intended outcome (faster weaning).
• Synapse Biomedical: Synapse Biomedical manufactures the NeuRx DPS Diaphragm Pacing System, a phrenic nerve/diaphragm stimulation platform with FDA humanitarian device exemption for ventilator weaning in spinal cord injury - directly competes with Stimdia in mechanism and respiratory indication.
• Lungpacer Medical: Lungpacer Medical develops a phrenic nerve stimulation system (Diaphragm Pacing Therapy) explicitly designed to assist weaning of mechanically ventilated ICU patients - the most direct competitor to Stimdia's SPAIRO System in indication, mechanism, and target customer.

Broad incumbents

• Inspire Medical Systems: Inspire is an established neuromodulation company commercializing hypoglossal nerve stimulation for obstructive sleep apnea - a public-market precedent for scaling an implantable neurostim in a respiratory/sleep indication, and a useful commercial benchmark for SPAIRO's potential trajectory.
• Medtronic: Medtronic operates one of the broadest neuromodulation portfolios (spinal cord, deep brain, sacral nerve, gastric) along with a respiratory and patient monitoring business - a relevant incumbent both as potential competitor and strategic acquirer in ICU-adjacent neuromodulation.
• Fisher & Paykel Healthcare: Fisher & Paykel Healthcare is a global respiratory care and humidification incumbent with deep hospital channel penetration in mechanical ventilation and airway clearance - a meaningful comparator for unit economics, sales motion, and global expansion potential of SPAIRO.
• Avanos Medical: Avanos Medical sells respiratory health products including closed-suction catheters and airway clearance devices used in ICU ventilated patients - a relevant incumbent in the same ICU customer base and value-analysis committee pathway.
• Boston Scientific Neuromodulation: Boston Scientific is a global medtech incumbent with a large neuromodulation franchise (spinal cord stim, deep brain stim, RF ablation) and the originator of much of Stimdia's leadership team - a strategic acquirer and benchmark for category scale.

Emerging players

• Nalu Medical: Nalu Medical is a venture-backed peripheral nerve stimulation company (Stimdia CEO Allen Meacham was previously CRO) - directly comparable neuromodulation platform targeting chronic pain, with overlapping leadership DNA and a similar commercial-stage inflection path.
• Vapotherm: Vapotherm develops high-flow nasal cannula systems for respiratory distress - comparable in being a clinical-stage-to-commercial respiratory device company selling into ICU/hospital channels with similar capital equipment and reimbursement dynamics.

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/stimdia-medical-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stimdia Medical